2018
Changing incidence of factitious renal stone disease.
Ghali F, Dagrosa L, Moses R, Ursiny M, Eisner B, Pais V. Changing incidence of factitious renal stone disease. Clinical Nephrology 2018, 90: 102-105. PMID: 29882511, DOI: 10.5414/cn109331.Peer-Reviewed Original Research
2017
Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice
Caballero D, Li Y, Fetene J, Ponsetto J, Chen A, Zhu C, Braddock DT, Bergwitz C. Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice. PLOS ONE 2017, 12: e0180098. PMID: 28704395, PMCID: PMC5509111, DOI: 10.1371/journal.pone.0180098.Peer-Reviewed Original ResearchConceptsRenal calcificationCompared to WT miceElevated urinary excretionRenal stone diseaseNucleotide pyrophosphatase phosphodiesterase 1WT miceDietary calciumUrinary excretionIntraperitoneal administrationStone diseaseNull miceMouse mutationMiceCalcificationNephrocalcinosisNpt2aDisordersUnrecognized factorsContribution of genotypePresent studyPhosphodiesterase 1PPINpt2cPatientsNephrolithiasisResponse of Npt2a knockout mice to dietary calcium and phosphorus
Li Y, Caballero D, Ponsetto J, Chen A, Zhu C, Guo J, Demay M, Jüppner H, Bergwitz C. Response of Npt2a knockout mice to dietary calcium and phosphorus. PLOS ONE 2017, 12: e0176232. PMID: 28448530, PMCID: PMC5407772, DOI: 10.1371/journal.pone.0176232.Peer-Reviewed Original ResearchConceptsCompared to WT miceWT miceDietary calciumDietary phosphateCalcium x phosphorus productUrine phosphate levelsUrinary calcium excretionUrine anion gapDevelopment of novel therapiesWild-typeRenal stone diseaseWild-type miceNpt2a-knockout (KO) miceCalcium excretionFGF23 levelsNovel therapiesPreventing nephrolithiasisPlasma phosphateStone diseaseAnion gapAddition of calciumKnockout micePhosphorus productCalcium phosphate depositionHuman carriers
2016
Impaired urinary osteopontin excretion in Npt2a−/− mice
Caballero D, Li Y, Ponsetto J, Zhu C, Bergwitz C. Impaired urinary osteopontin excretion in Npt2a−/− mice. American Journal Of Physiology. Renal Physiology 2016, 312: f77-f83. PMID: 27784695, PMCID: PMC5283892, DOI: 10.1152/ajprenal.00367.2016.Peer-Reviewed Original ResearchConceptsOPN gene expressionUrinary excretionRenal phosphate wasting disordersHigh-phosphate dietPhosphate wasting disordersOral phosphate supplementationRenal gene expressionRenal stone diseaseGene expressionAdditional risk factorsOPN levelsRole of OPNWasting disordersStone diseaseUrine excretionMouse modelNpt2aRisk factorsMouse mutationPhosphate supplementationRenal phosphateMiceRestored to wild-type levelsExcretionNephrocalcinosis
2014
Neue Einblicke in die Pathogenese der Nierensteine
Knauf F. Neue Einblicke in die Pathogenese der Nierensteine. Die Nephrologie 2014, 9: 196-203. DOI: 10.1007/s11560-013-0850-0.Peer-Reviewed Original ResearchRenal stone diseaseStone diseaseMajority of patientsMethodsThis review articleNovel therapeutic agentsPathogenesis of nephrolithiasisSelective literature researchUrine volumeRisk factorsUrine collectionUrine pHCalcium stonesTherapeutic approachesMouse modelStone formationInflammasome responseTherapeutic agentsKidney stonesStone analysisUric acidConcentration of calciumPathogenesisDiseaseReview articleChronic problems
2012
Urinary Metabolic Phenotyping the slc26a6 (Chloride–Oxalate Exchanger) Null Mouse Model
Garcia-Perez I, Villaseñor A, Wijeyesekera A, Posma JM, Jiang Z, Stamler J, Aronson P, Unwin R, Barbas C, Elliott P, Nicholson J, Holmes E. Urinary Metabolic Phenotyping the slc26a6 (Chloride–Oxalate Exchanger) Null Mouse Model. Journal Of Proteome Research 2012, 11: 4425-4435. PMID: 22594923, PMCID: PMC4028149, DOI: 10.1021/pr2012544.Peer-Reviewed Original ResearchConceptsRenal stone diseaseStone diseaseNull miceUrinary metabolic signaturesBlood pressure controlWild-type miceNull mouse modelRenal stone formationRenal proximal tubulesUrinary metabolicUrinary metabolomeClear metabolic differentiationSodium homeostasisRenal stonesType miceMouse modelUrinary metabolitesOxalate balanceUrinary profilesProximal tubulesPressure controlStone formationExchanger SLC26A6Metabolic signaturesPathological processes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply